Trial Watch: Adoptive cell transfer immunotherapy. - Wikidata - awgldk - TriplyDB

Trial Watch: Adoptive cell transfer immunotherapy.

Trial Watch: Adoptive cell transfer immunotherapy.

http://www.wikidata.org/entity/Q36057432

about

Trial Watch Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State Trial Watch: Adoptive cell transfer for oncological indications The progress of immunotherapy for glioblastoma Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Pathways and therapeutic targets in melanoma Trial watch: IDO inhibitors in cancer therapy Trial watch: Dendritic cell-based anticancer therapy Trial watch: Cardiac glycosides and cancer therapy Chemical metabolic inhibitors for the treatment of blood-borne cancers Trial watch: Immunostimulatory cytokines in cancer therapy.Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.Classification of current anticancer immunotherapies Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer.Trial Watch: Immunostimulatory cytokines.Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Trial watch: Dendritic cell-based interventions for cancer therapy Trial watch: Prognostic and predictive value of the immune infiltrate in cancer Trial watch: Peptide vaccines in cancer therapy Trial watch: DNA vaccines for cancer therapy.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Trial watch: Oncolytic viruses for cancer therapy An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer.A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Specific immunotherapy in renal cancer: a systematic review.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.Basic principles of tumor-associated regulatory T cell biology.Developing melanoma therapeutics: overview and update.Cancer immunotherapy: accomplishments to date and future promise.Evolving role of tumor antigens for future melanoma therapies.The role of oncolytic virus immunotherapies to subvert cancer immune evasion.Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review.Specific immunotherapy in hepatocellular cancer: A systematic review.Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.Rejuvenated T cells attack old tumors New immunotherapeutic paradigms for castration-resistant prostate cancer.Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

P2860

Q24618653-C72FEB22-48C6-46A1-8B92-F727C634719B Q26782573-D848E08A-8D21-4C80-8E4B-71E46477A571 Q26785545-7E33040B-3539-4FA8-8B18-36264648A8E2 Q26797282-315A4C80-B7E8-4F33-8DB7-FFCDACBDDFF4 Q26852437-668E46A4-E0CA-4CEE-9895-33F25FAF813F Q26865736-10B69185-0847-40C1-B757-2DAB66647227 Q27006866-EF403185-AAA3-4B8E-9B1A-5EC8E4294537 Q27024047-33049FB3-A43A-4FCB-8278-708449CEF233 Q28395830-77291313-74E1-426A-99D3-3FC09B00A550 Q28822335-79EB4291-9B24-40A4-886C-371AC9C3B495 Q33880165-4562ED3B-309C-425A-852F-A195BBAE6959 Q34859794-4F6448E5-0B28-4D32-8CAA-F2CE6AE2139C Q34871657-2E8752AC-C294-4259-B046-6DD22AEF9B4A Q35149637-7B0E025E-9DB2-448B-B487-4ADEEEF239E4 Q35968018-68B2659B-7FDF-470F-93F9-1C007153BA2A Q36057492-307A05DC-7435-4601-8403-187982B94ADF Q36373370-DFEB7620-01B9-46D2-AA57-7DBA694D449F Q36388529-41F3371C-58C1-4F9C-B2C1-6977B5975784 Q36456483-FD9296A4-9755-428F-9E8F-B1D3141C94FA Q36476100-20131C45-C488-4B66-82A1-4577A6699A5C Q36845824-4A4E3D9E-2F9C-410B-83AD-257E8453B5D5 Q36887833-117CE364-AD2D-4725-A2F1-AA7BAF8456A2 Q37028023-F7CBD10C-9EE2-4965-9D52-CDCCDCD8E7D9 Q37488222-022A349A-CECB-45E4-B388-B7008476545B Q37555940-010F7F9A-04AE-422B-948B-3702D1E4F5A9 Q37632182-2A520542-1085-4003-8538-B3ADFC2A18DF Q37652790-69213415-6923-4537-A4E8-7977C039C8AD Q37690444-87A1C51D-B7B1-4FDE-A338-C1339675E21B Q38045603-F7E7B0C2-BFE4-47EB-B956-8F84C9E9064D Q38081406-491D2A35-DF0C-4882-9A80-19EA95C3ADF7 Q38151738-FDA3EC6B-D117-45A2-9CBB-243EBF83E556 Q38232855-0571271A-E6D6-4F3C-A01F-77A4D6AE8A60 Q38357137-0136A29F-C28E-4CAA-8645-84F049DE6A9D Q38544057-3A7697A5-D942-452E-9E3C-9F9D7F712117 Q38840178-F2EE5C92-8A67-4A9D-A962-9F8C711EAA42 Q39277283-C877567C-C8A8-4C7B-B19B-B97D70E52AF7 Q42097613-87C1A446-4E9B-4B85-9459-DE005871AFC8 Q42344607-506AC2CB-106B-4A1A-A4A9-A097CA36902B Q42380935-C52A43FD-D6B3-4C4C-8AA7-29E54163C185 Q42702234-01E29328-05DA-4BCA-A743-83C62917E170

P2860

Trial Watch: Adoptive cell transfer immunotherapy.

http://www.wikidata.org/entity/Q36057432

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Trial Watch: Adoptive cell transfer immunotherapy.

@ast

Trial Watch: Adoptive cell transfer immunotherapy.

@en

type

label

Trial Watch: Adoptive cell transfer immunotherapy.

@ast

Trial Watch: Adoptive cell transfer immunotherapy.

@en

prefLabel

Trial Watch: Adoptive cell transfer immunotherapy.

@ast

Trial Watch: Adoptive cell transfer immunotherapy.

@en

P1433

Q36057432-84FDBCF9-A492-4AA9-94E8-0DB800EAD6A9

P1476

Q36057432-DA064E1B-1A18-433E-BCD4-E440301D9A32

P2860

Q36057432-06F840D2-C4D8-432C-9904-690C5A5B3857

Q36057432-098BF84D-CD92-4D67-8037-CD7463CD8B9F

Q36057432-098C0ADA-D534-44E5-B7F3-2055A2F537E9

Q36057432-0A13A3E9-0370-4ED6-9772-28A539AC753B

Q36057432-13E324D9-6564-4A84-A80F-165CF1E50820

Q36057432-18531A11-EB31-4D60-82B7-CB5AA6355C8D

Q36057432-1925A46E-AF49-4A93-BCE6-0CBE93631F36

Q36057432-19D0178E-626C-4132-8A93-9E09C7D122E5

Q36057432-1A0F1038-756C-432F-8C30-3EFBC2FFFAFD

Q36057432-1BC0B70F-1668-443C-B773-CDF105004370

P304

Q36057432-69060143-E601-433A-AD9F-BD411AF9DCF0

P31

Q36057432-D05A6DBB-1074-453E-A399-2F85C74B27E8

P356

Q36057432-E8F18F6F-B22B-41DB-BCE6-B7FE5AF3EE72

P433

Q36057432-00CD62FE-C896-41BB-9DF7-F5481BC48EA5

P478

Q36057432-21BE1CED-B5F3-4C76-823C-471988F1EBCE

P50

Q36057432-00492C8E-957D-42DF-AB8E-F35F43FFF795

Q36057432-1B0B8AE3-A7C9-452E-8559-B2205C299946

Q36057432-3A027ACD-197C-45A0-B1FC-5EA9284F9FDF

Q36057432-59A4E00A-25F0-4F38-968A-F415018F5365

Q36057432-5A27A9CB-C538-4316-B18A-DFB10A5F068B

Q36057432-7EB27F87-6992-4B44-BA34-FE81BD9ED272

Q36057432-C506A502-3037-4602-9C51-3911BC2FE937

Q36057432-D679291C-4F53-4F36-B3AF-044DDDDBAD6D

Q36057432-DFFC2B14-7127-4F53-9599-368E479B974B

P577

Q36057432-F6265585-7AD6-4618-A231-52D17EE81F1B

P5875

Q36057432-14249838-F8CB-4DB3-8A8D-81C8B02E9DF4

P698

Q36057432-B96AE050-52B5-4EBC-AD4E-8CC7ED2B5701

P921

Q36057432-8DE4D0CA-967D-4CE7-A29D-28B57EC95D79

P932

Q36057432-3F906FA5-6BD9-433C-8A2B-226B2002DB86

P356

P1433

P1476

Trial Watch: Adoptive cell transfer immunotherapy.

@en

P2860

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Adoptive immunotherapy for cancer: building on success

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Cancer immunotherapy: moving beyond current vaccines

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

P304

306-315

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.19549

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Lorenzo Galluzzi

Laurence Zitvogel

Alexander Eggermont

Catherine Sautès-Fridman

Erika Vacchelli

Wolf Hervé Fridman

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228072412

http://www.w3.org/2001/XMLSchema#string

P698

22737606

http://www.w3.org/2001/XMLSchema#string

P921

P932

3382856

http://www.w3.org/2001/XMLSchema#string